Breast Cancer Prevention Study Sets Up Generic Competition
This article was originally published in The Pink Sheet Daily
Executive Summary
Aromasin now has data that could set it up as the new standard of preventive care for invasive breast cancer, but as the drug lost patent protection in April, it is unclear how Pfizer will proceed.